KB803
KB803-EYE-01
Phase 3 mab active
Quick answer
KB803 for Dystrophic Epidermolysis Bullosa is a Phase 3 program (mab) at Krystal Biotech Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Krystal Biotech Netherlands B.V.
- Indication
- Dystrophic Epidermolysis Bullosa
- Phase
- Phase 3
- Modality
- mab
- Status
- active